Contrast enhanced ultrasound with Lumason for Carcinoma, Renal Cell

Phase-Based Estimates
Indiana University Hospital, Indianapolis, IN
Carcinoma, Renal Cell+2 More
Contrast enhanced ultrasound with Lumason - Drug
All Sexes
Eligible conditions
Carcinoma, Renal Cell

Study Summary

This study is evaluating whether contrast enhanced ultrasound can be used to predict the pathologic grade of renal cell carcinoma.

See full description

Eligible Conditions

  • Carcinoma, Renal Cell
  • Cancer
  • Neoplasms
  • Renal Malignant Tumor

Treatment Effectiveness

Effectiveness Estimate

3 of 3
This is better than 93% of similar trials

Study Objectives

This trial is evaluating whether Contrast enhanced ultrasound with Lumason will improve 1 primary outcome in patients with Carcinoma, Renal Cell. Measurement will happen over the course of first 6 months.

first 6 months
Correlation of contrast enhanced ultrasound features of renal masses with pathologic grade

Trial Safety

Safety Estimate

3 of 3
This is better than 85% of similar trials

Trial Design

2 Treatment Groups

Renal malignancy

This trial requires 40 total participants across 2 different treatment groups

This trial involves 2 different treatments. Contrast Enhanced Ultrasound With Lumason is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.

Renal malignancy
Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason
ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: first 6 months
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly first 6 months for reporting.

Who is running the study

Principal Investigator
J. K. S.
Prof. Jordan K. Swensson, Assistant Professor of Clinical Radiology
Indiana University

Closest Location

Indiana University Hospital - Indianapolis, IN

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Greater than or equal to 18 years of age
The renal mass that was previously identified through radiology and clinical features is consistent with RCC. show original
The clinical care plan includes having part or all of the kidney removed. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of carcinoma, renal cell?

Add answer

Signs of carcinoma, renal cell include a lump, persistent pain, a rough, hot or tender bone that feels hard to palpation over, and unexplained weight loss. There may also be blood in the urine or blood in the stool.\n

Unverified Answer

What causes carcinoma, renal cell?

Add answer

Carcinoma, renal cell, is likely to be caused by a combination of multiple environmental factors. Since the risk of developing carcinoma, renal cell, is also influenced by genetics, environmental factors may be linked. These factors may not be neatly separated from one another. A multi-centered study needs to establish the best approach to understanding the combined effects of all these factors in the risk of developing carcinoma, renal cell.

Unverified Answer

What are common treatments for carcinoma, renal cell?

Add answer

Rare cancers often involve major organ systems and respond only slowly to conventional treatment. The optimal and most appropriate treatment for these cancers may vary between disease subtypes. For aggressive forms of renal cell cancer, complete cystectomy followed by adjuvant chemotherapy is often prescribed. Surgical removal of the bladder followed by partial cystectomy after completion of adjuvant chemotherapy is particularly recommended in the setting of aggressive transitional cell carcinoma.

Unverified Answer

What is carcinoma, renal cell?

Add answer

Carcinoma, renal cell is a cancer of epithelial organs. The exact incidence of renal carcinoma is unknown. It may be an asymptomatic disease, rarely painful in men. Rarely it is detected at the stage of renal cortical metastasis. Diagnosis is most often made by pathological examination of the kidney. Most common types of renal cell carcinoma are transitional cell carcinoma, clear cell carcinoma and adenocarcinoma. Testicular cancer tends to present as undescended scrotum, painful penile swelling and flank enlargement.

Unverified Answer

How many people get carcinoma, renal cell a year in the United States?

Add answer

The number of persons with kidney carcinoma in each state is underestimated even when the data are adjusted for the population rate and the incidence of ESRD. Estimates from a population-based study of Medicare data indicate the incidence of renal cell carcinoma is approximately 25 times higher than the incidence of ESRD that would result from a population prevalence of 7.4 million adults with ESRD.

Unverified Answer

Can carcinoma, renal cell be cured?

Add answer

The overall survival rate of patients with carcinoma, renal cell is very low. Treatment of the metastatic site does not enhance the outcome in these patients. Local therapy achieves a survival improvement of 13.6 months only in patients with a synchronous metastatic disease. We can conclude the curability of carcinomas, renal cell must be considered in adjuvant treatment.

Unverified Answer

What does contrast enhanced ultrasound with lumason usually treat?

Add answer

The use of bolus-tracking CEUS is a safe, noninvisible and highly useful procedure for the performance of dynamic imaging and the diagnosis of malignant and benign lesions and their differential with renal cell carcinoma, both in the kidneys and in the upper abdominal and pelvic region. CEUS seems to be an excellent tool for detecting renal cell carcinoma, as well as metastasizing and nonmetastasizing metastatic lesions, which may be detected by dynamic imaging. Further prospective and larger-patient studies are required.

Unverified Answer

How serious can carcinoma, renal cell be?

Add answer

Results from a recent clinical trial of this study indicate that the mortality for renal cell carcinoma remains at high level. This discrepancy cannot be attributed exclusively to the demographic and clinicopathological features of patients with renal cell carcinoma. Results from a recent clinical trial suggests that more research is needed to investigate the pathogenesis contributing to the higher mortality of patients with renal cell carcinoma, and to implement appropriate interventions to improve the clinical outcomes of these patients.

Unverified Answer

What is the survival rate for carcinoma, renal cell?

Add answer

Although this information is important and is needed, no one is fully aware of the prognosis of the treatment they receive for RCC. A patient's survival rate is dependent on their treatment and tumour type.

Unverified Answer

What is contrast enhanced ultrasound with lumason?

Add answer

CEUS can be used as non invasive tool with high specificity to detect malignant pathologies, in particular malignant renal tumors. This application is very simple to perform and can be of great clinical value, as malignant tumors are frequently vascularized.

Unverified Answer

What are the latest developments in contrast enhanced ultrasound with lumason for therapeutic use?

Add answer

Ultrasonic contrast agent based sonomagrams provide important information on tumor architecture, blood flow and vessel anatomy. The contrast enhanced sonographic appearance of the lesions in the kidney has been demonstrated to provide an initial assessment of renal vascularity and has the potential to be used as an adjunct to CT-guided intervention.

Unverified Answer

Is contrast enhanced ultrasound with lumason typically used in combination with any other treatments?

Add answer

Despite its growing presence as a complementary examination in endourology, CE-US is not typically used, nor is it used in combination with any other treatment, in most clinical practice at the present time because its value has not been demonstrated in the absence of treatment.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma, Renal Cell by sharing your contact details with the study coordinator.